81025-83-4

Usage

Uses

Used in Pharmaceutical Industry:
(R)-(+)-3-METHYLSUCCINIC ACID 1-MONOMETHYL ESTER is used as a key intermediate in the synthesis of chiral drugs for the treatment of various medical conditions. Its unique stereochemistry allows for the development of enantiomerically pure compounds, which can exhibit different biological activities and reduce potential side effects associated with racemic mixtures.
Used in Agrochemical Industry:
(R)-(+)-3-METHYLSUCCINIC ACID 1-MONOMETHYL ESTER is used as a precursor in the production of chiral agrochemicals, such as insecticides, herbicides, and fungicides. Its ability to impart specific stereochemistry to the final product can lead to improved efficacy and selectivity, reducing the environmental impact of these chemicals.
Used in Specialty Chemicals:
(R)-(+)-3-METHYLSUCCINIC ACID 1-MONOMETHYL ESTER is used as a building block in the synthesis of various specialty chemicals, including chiral ligands, catalysts, and chiral auxiliaries. Its unique structural features and optical activity make it a valuable component in the development of new materials with specific properties and applications.
Used in Research and Development:
(R)-(+)-3-METHYLSUCCINIC ACID 1-MONOMETHYL ESTER is used as a research compound in the study of asymmetric synthesis, chiral recognition, and stereoselective reactions. Its unique properties provide valuable insights into the mechanisms of chiral interactions and the development of new synthetic methodologies.
Used in the Preparation of Triazole-Containing Macrocycles:
(R)-(+)-3-METHYLSUCCINIC ACID 1-MONOMETHYL ESTER is used as a starting material in the synthesis of triazole-containing macrocycles, which have potential applications in various fields, such as supramolecular chemistry, drug discovery, and materials science. Its ability to form stable macrocyclic structures with triazole moieties can lead to the development of new compounds with unique properties and functions.

InChI:InChI=1/C6H10O4/c1-4(6(8)9)3-5(7)10-2/h4H,3H2,1-2H3,(H,8,9)/t4-/m1/s1

Upstream product

• 22644-27-5 (R)-methylsuccinic acid dimethyl ester 
• 7338-27-4 4-methoxy-2-methylene-4-oxobutanoic acid 
• 21307-96-0 methyl 2-methylsuccinate 
• 67-56-1 methanol 
• 4100-80-5 2-methylsuccinic anhydride 
• 498-21-5 2-methylbutanedioic acid 
• 3641-51-8 2-(R)-methylsuccinic acid 
• 143225-23-4 2(R)-Methyl-4-Benzyl Succinate 
• 617-54-9 citraconic acid dimethyl ester 
• 498-23-7 citraconic acid 
• 97-65-4 2-methylenesuccinic acid 
• 623-43-8 crotonic acid methyl ester 

Downstream Products

• 185836-75-3 (R)-3-tert-butyloxycarbonyl-2-methylpropanoic acid 
• 154634-38-5 (R,R)-2,3-dimethyl-succinic acid monomethyl ester 
• 1267640-52-7 C₂₂H₂₉N₅O₄ 
• 1174194-07-0 (R)-3-methyl-5-phenylpent-4-yn-1-ol 
• 1384132-79-9 (R)-(5-bromo-3-methylpent-1-ynyl)benzene 
• 1432125-13-7 methyl 4-(2-{4-[({2-[(3-{[(2-{[(2R)-4-methoxy-2-methyl-4-oxobutanoyl](methyl)amino}ethyl)(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]phenyl}ethyl)benzoate 
• 1351949-97-7 C₃₂H₄₄N₆O₆ 
• 1351949-91-1 C₂₂H₃₁N₅O₄ 
• 1351949-75-1 C₂₉H₃₇N₃O₅ 
• 1351949-59-1 C₁₉H₂₄N₂O₃ 
• 1351948-95-2 C₃₂H₄₂N₆O₆ 
• 1351948-90-7 C₂₂H₂₉N₅O₄ 

Relevant academic research and scientific papers

Application of Transition-Metal Catalysis, Biocatalysis, and Flow Chemistry as State-of-the-Art Technologies in the Synthesis of LCZ696

LCZ696 is a novel treatment for patients suffering from heart failure that combines the two active pharmaceutical ingredients sacubitril and valsartan in a single chemical compound. While valsartan is an established drug substance, a new manufacturing process suitable for large-scale commercial production had to be developed for sacubitril. The use of chemocatalysis, biocatalysis, and flow chemistry as state-of-the-art technologies allowed to efficiently build up the structure of sacubitril and achieve the defined performance targets.

Modular 1,1′-Ferrocenediyl-cored P-Stereogenic Diphosphines: ′′JDayPhos′′ Series and its Use in Rhodium(I)-Catalyzed Hydrogenation

A novel ferrocene-based P-stereogenic diphospine ligand series dubbed JDayPhos was developed, which rhodium(I) complexes of some of its members exhibited excellent enantioselectivity (up to >99% ee) and high activity in asymmetric hydrogenation of β-unsubstituted or -substituted itaconates and α-methylene-γ-oxo-carboxylates. (Figure presented.).

CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES

The present invention relates to Compounds of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R1, R2, R3, R4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.

Enantioselective Formal C?H Conjugate Addition of Acetanilides to β-Substituted Acrylates by Chiral Iridium Catalysts

The Ir-catalyzed enantioselective reaction of substituted acetanilides with β-substituted α,β-unsaturated esters provided chiral 3,3-disubstituted propanoates in high yield with good-to-excellent enantiomeric excess (up to 99 % ee). This transformation, i

SPIROBENZYLAMINE-PHOSPHINE, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention relates to a spirobenzylamine-phosphine, preparation method therefor and use thereof. The compound has a structure represented by formula (I), wherein n=0 to 3; R1, R2, R3, R4, R5, R6, R7, R8 and R9 having a value as defined in claim 1. Starting from the substituted 7-trifluoromesyloxy-7'-diarylphosphino-1, 1'-spiro-dihydroindene, the compound is synthesized in a two-step or three-step reactions. The new spirobenzylamine-phosphine is complexed with an iridium precursor and is subjected to ion exchange, to give an Iridium/spirobenzylamine-phosphine complex comprising various anions. The spiro benzyl amine-phosphine/Iridium complex according to the present invention may be used for catalyzing asymmetry hydrogenation of a variety of alpha-substituted acrylic acids, has high activity and enantio-selectivity, and has a good prospect of industrialization.

Spirobenzylamine-Phosphine, Preparation Method Therefor And Use Thereof

The present invention relates to a spirobenzylamine-phosphine, preparation method therefor and use thereof. The compound has a structure represented by formula (I), wherein n=0 to 3; R1, R2, R3, R4, R5, R6, R7, R8 and R9 having a value as defined in claim 1. Starting from the substituted 7-trifluoromesyloxy-7′-diarylphosphino-1,1′-spiro-dihydroindene, the compound is synthesized in a two-step or three-step reactions. The new spirobenzylamine-phosphine is complexed with an iridium precursor and is subjected to ion exchange, to give an Iridium/spirobenzylamine-phosphine complex comprising various anions. The spiro benzyl amine-phosphine/Iridium complex according to the present invention may be used for catalyzing asymmetry hydrogenation of a variety of alpha-substituted acrylic acids, has high activity and enantio-selectivity, and has a good prospect of industrialization.

A convergent approach to (-)-callystatin a based on local symmetry

The key is symmetry! A convergent synthetic approach of the highly cytotoxic natural product (-)-callystatin A was developed assembling three fragments through Julia-Kocienski olefination and Stille cross-coupling. The new strategy relies on a pivotal local symmetry of the target molecule. In this preliminary study, particular attention was devoted to facilitate the catalytic enantiocontrol of strategic stereogenic centers present in each of the fragments (see scheme). Copyright

A three-enzyme system involving an ene-reductase for generating valuable chiral building blocks

The use of ene-reductase (ERED) enzymes for the asymmetric reduction of olefins offers a green, renewable alternative to metal-catalysed asymmetric reduction. We report herein the first example of an ERED-catalysed enantiospecific reduction carried out at large scale using a carbonyl reductase (CRED) enzyme in the cofactor recycle. This reaction has been paired with a hydrolase-mediated regioselective ester hydrolysis to generate a valuable chiral building block using a straightforward one-pot process. Copyright

Enantioselective hydrogenation of α-substituted acrylic acids catalyzed by iridium complexes with chiral spiro aminophosphine ligands

Highly active: Iridium complexes with chiral spiro aminophosphine ligands were synthesized and applied as catalysts for the asymmetric hydrogenation of α-substituted acrylic acids (see scheme). The complexes were highly active catalysts, showing turnover frequencies of up to 6000 h-1, and catalyst loadings could be reduced to 0.01 mol %. Copyright

Catalytic asymmetric alkynylation and arylation of aldehydes by an H 8-binaphthyl-based amino alcohol ligand

A novel chiral H8-1,1'-binaphthyl-based amino alcohol ligand (1Ra,2S,3R)-2 has been synthesized and applied in the direct nucleophilic addition of organozincs (alkynylzinc and arylzinc prepared in situ) to aldehydes, yielding the corresponding optically active propargylic alcohols and diarylmethanols in high yields and good to excellent enantioselectivities. For the asymmetric arylation reaction, one catalyst (1Ra,2S,3R)-2 can afford both enantiomers of many pharmaceutically interesting diarylmethanols by a proper combination of various arylzinc reagents and aldehydes.